UNSPSC 51294512: Paroxetine

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41VRH5220H. European Medicines Agency schedules Paroxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Paroxetine generally arises in the molecular formula C19H20FNO3.

UNSPSC 51294512 Paroxetine is a Commodity code covering pharmaceutical products, but the recent state and local opportunities tagged under it diverge significantly from the code's nominal scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking procurement of naloxone and drug deactivation systems on an annual basis through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor information about implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The code shows limited recent activity directly aligned with paroxetine procurement; the opportunities indexed under it reflect broader pharmaceutical and health-supply purchasing rather than a specific antidepressant product line.

State and local governments are soliciting pharmaceuticals and health products through traditional RFP and competitive bidding channels, with issuing bodies including county health departments, state departments of health and human services, and multistate cooperative purchasing alliances serving multiple jurisdictions. Activity is concentrated in Florida and Minnesota, with multistate participation through MMCAP extending to Oregon. When state and local entities do procure pharmaceuticals in this space, they typically require compliance with FDA requirements, cGMP certification, Drug Supply Chain Security Act compliance, and established relationships with authorized wholesalers such as AmerisourceBergen, Cardinal Health, and Morris & Dickson. Vendors must maintain substantial insurance coverage and accept administrative fees or performance penalties. The code itself does not show active demand for paroxetine specifically; procurement appears instead to follow commodity aggregation models through cooperative purchasing vehicles or episodic health-crisis demand (as with naloxone procurement during opioid response initiatives).